A. Ks, Treatment-resistant depression: therapeutic trends, challenges, and future directions, Patient Prefer Adherence, vol.6, pp.369-388, 2012.

, Diagnostic and statistical manual of mental disorders, 5th edn, American Psychiatric Association, 2013.

A. E. Autry and L. M. Monteggia, Brain-derived neurotrophic factor and neuropsychiatric disorders, Pharmacol Rev, vol.64, pp.238-258, 2012.

C. Björkholm and L. M. Monteggia, BDNF -a key transducer of antidepressant effects, Neuropharmacology, vol.102, pp.72-79, 2016.

O. Burstein, M. Franko, E. Gale, A. Handelsman, S. Barak et al., Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression, PLoS One, vol.12, 2017.

P. Carmeliet, L. Kieckens, L. Schoonjans, M. Cole, R. Bronson et al., Plasminogen activator Inhibitor-1 gene-deficient mice, J Clin Invest, vol.92, pp.2746-2755, 1993.

P. Carmeliet, L. Schoonjans, L. Kieckens, B. Ream, J. Degen et al., Physiological consequences of loss of plasminogen activator gene function in mice, Nature, vol.368, pp.419-424, 1994.

A. Caspi, K. Sugden, T. E. Moffitt, A. Taylor, I. W. Craig et al., Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene, Science, vol.301, pp.386-389, 2003.

E. Castrén and T. Rantamäki, The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity, Dev Neurobiol, vol.70, pp.289-297, 2010.

C. H. Chang, M. C. Chen, M. H. Qiu, and J. Lu, Ventromedial prefrontal cortex regulates depressive-like behavior and rapid eye movement sleep in the rat, Neuropharmacology, vol.86, pp.125-132, 2014.

R. Doron, D. Lotan, Z. Versano, L. Benatav, M. Franko et al., Escitalopram or novel herbal mixture treatments during or following exposure to stress reduce anxiety-like behavior through corticosterone and BDNF modifications, PLoS One, vol.9, 2014.

S. C. Dulawa, K. A. Holick, B. Gundersen, and R. Hen, Effects of chronic fluoxetine in animal models of anxiety and depression, Neuropsychopharmacology, vol.29, pp.1321-1330, 2004.

W. El-hage, S. Leman, V. Camus, and C. Belzung, Mechanisms of antidepressant resistance, Front Pharmacol, vol.4, p.146, 2013.

F. Eskandari, S. Mistry, P. E. Martinez, S. Torvik, C. Kotila et al., Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk, Metabolism, vol.54, pp.918-924, 2005.

J. Guintivano and Z. A. Kaminsky, Role of epigenetic factors in the development of mental illness throughout life, Neurosci Res, vol.102, pp.56-66, 2016.

M. Hamon and P. Blier, Monoamine neurocircuitry in depression and strategies for new treatments, Prog Neuro-Psychopharmacol Biol Psychiatry, vol.45, pp.54-63, 2013.

A. Holmes and R. J. Rodgers, Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioral effects of fluoxetine and phenelzine, 2003.

, Eur J Pharmacol, vol.459, pp.2874-2875

R. D. Idell, G. Florova, A. A. Komissarov, S. Shetty, R. Girard et al., The fibrinolytic system: a new target for treatment of depression with psychedelics, Med Hypotheses, vol.100, pp.46-53, 2017.

W. W. Ishak, J. Mirocha, D. James, G. Tobia, J. Vilhauer et al., Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up, Acta Psychiatr Scand, vol.131, pp.51-60, 2015.

E. Isingrini, C. Belzung, A. Audiffret, and V. Camus, Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging, Am J Geriatr Psychiatry, vol.19, pp.335-346, 2011.

A. J. Jasinska, C. A. Lowry, and M. Burmeister, Serotonin transporter gene, stress and raphe-raphe interactions: a molecular mechanism of depression, Trends Neurosci, vol.35, pp.395-402, 2012.

H. Jiang, X. Li, S. Chen, N. Lu, Y. Yue et al., Plasminogen activator Inhibitor-1 in depression: results from animal and clinical studies, Sci Rep, vol.6, p.30464, 2016.

E. A. Khawam, G. Laurencic, and D. A. Malone, Side effects of antidepressants: an overview, Cleve Clin J Med, vol.73, pp.351-353, 2006.

K. Lahlou-laforet, M. Alhenc-gelas, M. Pornin, S. Bydlowski, E. Seigneur et al., Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease, Am J Cardiol, vol.97, pp.1287-1291, 2006.

M. A. Lebow and A. Chen, Overshadowed by the amygdala: the bed nucleus of the stria terminalis emerges as key to psychiatric disorders, Mol Psychiatry, vol.21, pp.450-463, 2016.

R. Lee, P. Kermani, K. K. Teng, and B. L. Hempstead, Regulation of cell survival by secreted Proneurotrophins, Science, vol.294, pp.1945-1948, 2001.

N. Lopizzo, B. Chiavetto, L. Cattane, N. Plazzotta, G. Tarazi et al., Gene-environment interaction in major depression: focus on experience-dependent biological systems, Front Psychiatry, vol.6, p.68, 2015.

V. Lorenzetti, N. B. Allen, A. Fornito, and M. Yücel, Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies, J Affect Disord, vol.117, pp.1-17, 2009.

B. Lu, P. T. Pang, and N. H. Woo, The yin and yang of neurotrophin action, Nat Rev Neurosci, vol.6, pp.603-614, 2005.

L. Mao, N. Kawao, Y. Tamura, K. Okumoto, K. Okada et al., Plasminogen activator Inhibitor-1 is involved in impaired bone repair associated with diabetes in female mice, PLoS One, vol.9, 2014.

P. S. Masand and S. Gupta, Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine, 2002.

, Ann Clin Psychiatry Off J Am Acad Clin Psychiatr, vol.14, pp.175-182

K. A. Matthews, L. L. Schott, J. Bromberger, J. Cyranowski, S. A. Everson-rose et al., Associations between depressive symptoms and inflammatory/ hemostatic markers in women during the menopausal transition, Psychosom Med, vol.69, pp.124-130, 2007.

A. A. Moustafa, Increased hippocampal volume and gene expression following cognitive behavioral therapy in PTSD, Front Hum Neurosci, vol.7, 2013.

C. Otte, S. M. Gold, B. W. Penninx, C. M. Pariante, A. Etkin et al., Major depressive disorder, Nat Rev Dis Primer, vol.2, p.16065, 2016.

P. T. Pang, H. K. Teng, E. Zaltsev, N. T. Woo, K. Sakata et al., Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity, Science, vol.306, pp.487-491, 2004.

R. Pawlak, A. M. Magarinos, J. Melchor, B. Mcewen, and S. Strickland, Tissue plasminogen activator in the amygdala is critical for stressinduced anxiety-like behavior, Nat Neurosci, vol.6, pp.168-174, 2003.

M. Polyakova, K. Stuke, K. Schuemberg, K. Mueller, P. Schoenknecht et al., BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis, J Affect Disord, vol.174, pp.432-440, 2015.

K. Pothakos, J. K. Robinson, I. Gravanis, D. A. Marsteller, S. L. Dewey et al., Decreased serotonin levels associated with behavioral disinhibition in tissue plasminogen activator deficient (tPA?/?) mice, Brain Res, vol.1326, pp.135-142, 2010.

J. L. Price and W. C. Drevets, Neural circuits underlying the pathophysiology of mood disorders, Trends Cogn Sci, vol.16, pp.61-71, 2012.

M. H. Rapaport, C. Clary, R. Fayyad, and J. Endicott, Quality-of-life impairment in depressive and anxiety disorders, Am J Psychiatry, vol.162, pp.1171-1178, 2005.

P. Saltiel and D. Silvershein, Major depressive disorder: mechanism-based prescribing for personalized medicine, Neuropsychiatr Dis Treat, vol.11, pp.875-888, 2015.

S. Soeda, S. Koyanagi, Y. Kuramoto, M. Kimura, M. Oda et al., Anti-apoptotic roles of plasminogen activator inhibitor-1 as a neurotrophic factor in the central nervous system, Thromb Haemost, vol.100, pp.1014-1020, 2008.

T. Sorregotti, J. Mendes-gomes, J. L. Rico, R. J. Rodgers, and R. L. Nunes-de-souza, Ethopharmacological analysis of the open elevated plusmaze in mice, Behav Brain Res, vol.246, pp.76-85, 2013.

Y. Tamura, N. Kawao, M. Yano, K. Okada, K. Okumoto et al., Role of plasminogen activator Inhibitor-1 in glucocorticoidinduced diabetes and osteopenia in mice, Diabetes, vol.64, pp.2194-2206, 2015.

M. Tang, P. Jiang, H. Li, H. Cai, Y. Liu et al., Antidepressantlike effect of n-3 PUFAs in CUMS rats: role of tPA/PAI-1 system, Physiol Behav, vol.139, pp.210-215, 2015.

H. K. Teng, K. K. Teng, R. Lee, S. Wright, S. Tevar et al., ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and Sortilin, J Neurosci, vol.25, pp.5455-5463, 2005.

S. Tsai, Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression, Oncotarget, vol.8, pp.113258-113268, 2017.

S. Tsai, C. Hong, Y. Liou, Y. Chen, and T. , Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response, Pharmacogenet Genomics, vol.18, pp.869-875, 2008.

R. Uher, J. L. Payne, B. Pavlova, and R. H. Perlis, Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV, Depress Anxiety, vol.31, pp.459-471, 2014.

T. Vos, A. A. Abajobir, K. H. Abate, C. Abbafati, K. M. Abbas et al., Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study, Lancet, vol.390, pp.1211-1259, 2016.

P. Willner and C. Belzung, Treatment-resistant depression: are animal models of depression fit for purpose?, Psychopharmacology, vol.232, pp.3473-3495, 2015.

P. Willner, J. Scheel-krüger, and C. Belzung, Resistance to antidepressant drugs: the case for a more predisposition-based and less hippocampocentric research paradigm, Behav Pharmacol, vol.25, pp.352-371, 2014.

N. H. Woo, H. K. Teng, C. Siao, C. Chiaruttini, P. T. Pang et al., Activation of p75NTR by proBDNF facilitates hippocampal long-term depression, Nat Neurosci, vol.8, pp.1069-1077, 2005.

C. Zhou, J. Zhong, B. Zou, L. Fang, J. Chen et al., Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression, PLoS One, vol.12, 2017.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations